Tesamorelin
aka Egrifta
Mechanism
Tesamorelin (Egrifta / Egrifta SV) is a stabilized analog of human GHRH(1-44) with a trans-3-hexenoic acid moiety at the N-terminus that protects against protease degradation. FDA-approved in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, it is the only FDA-approved GHRH analog for this indication. Off-label use for general body composition and visceral fat reduction in non-HIV populations is common but outside the approved label.
Identification
| CAS number | 218949-48-5 |
|---|---|
| Molecular formula | C221H366N72O67S |
| Sequence | YADAIFTNSY RKVLGQLSAR KLLQDIMSR QQGESNQERG ARARL |
| Typical dose | 2 mg/day subcutaneous (approved EGRIFTA); 1.4 mg/day (EGRIFTA SV); research use mirrors clinical dosing of 1–2 mg/day SC |
| Half-life | ~26–38 minutes (Wikipedia / literature); FDA label reports ~8 minutes (single SC dose, healthy subjects) |
Vendors selling Tesamorelin
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Peptide Partners | 20 mg | $122.00 | — | 99 |
| Glacier Aminos | 10 mg | $67.99 | — | 99 |
| Glacier Aminos | 20 mg | $67.99 | — | 99 |
| Moglabs | 5 mg | $50.00 | — | 96 |
| BioLongevity Labs | 8 mg | $115.00 | — | 96 |
| BioLongevity Labs | 10 mg | $149.97 | — | 96 |
| Crush Research | 20 mg | — | — | 95 |
| Orbitrex Peptides | 10 mg | $69.99 | — | 95 |
| Profound Aminos | 5 mg | $59.00 | — | 95 |
| Reta One Labs | 20 mg | $92.00 | — | 95 |
| Reta One Labs | 10 mg | $39.00 | — | 95 |
| Licensed Peptides | 10 mg | $899.95 | — | 95 |
| Licensed Peptides | 10 mg | $764.95 | — | 95 |
| Licensed Peptides | 10 mg | $152.99 | — | 95 |
| Licensed Peptides | 10 mg | $130.99 | — | 95 |
| Prime Peptides | 10 mg | $60.00 | — | 95 |
| Peptide Tech | — | $36.99 | — | 94 |
| Mile High Compounds | — | $79.99 | — | 94 |
| Forge Performance Co. | 10 mg | $60.00 | — | 94 |
| Amino Club | — | $69.99 | — | 93 |
| Hydro Research Peptides | 10 mg | $0.55 | — | 91 |
| Hydro Research Peptides | 6.98 mg | $1.20 | — | 91 |
| Skye Peptides | 10 mg | $60.00 | — | 90 |
| Peptidology | 10 mg | $75.00 | — | 89 |
| Peptide Plugs | 16 mg | $90.00 | — | 89 |
| Peptide Plugs | 10 mg | $70.00 | — | 89 |
| Sunrise Bioresearch | 20 mg | $97.04 | — | 88 |
| Sunrise Bioresearch | 100 mg | $475.53 | — | 88 |
| EZ Peptides | 10 mg | $88.00 | — | 85 |
| EZ Peptides | 10 mg | $68.00 | — | 85 |
| Simple Peptide | 2 mg | $109.00 | — | 85 |
| Simple Peptide | 10 mg | $75.00 | — | 85 |
| Peptidegurus | 5 mg | — | — | 84 |
| Peptidegurus | 20 mg | — | — | 84 |
| Ascension Peptides | 5 mg | $50.00 | — | 84 |
| Reta Peptide | 10 mg | — | — | 83 |
| Cocer Peptides | 10 mg | $160.00 | — | 82 |
| Blank Peptides | 10 mg | $75.00 | — | 81 |
| OROS Research | 5 mg | — | — | 79 |
| OROS Research | 16 mg | — | — | 79 |
| OROS Research | 10 mg | — | — | 79 |
| Texpeptide | 10 mg | $65.00 | — | 70 |
| Crystal Peptides | 5 mg | $44.99 | — | 66 |
| Crystal Peptides | 10 mg | $79.00 | — | 66 |
| Certified Peptides | 10 mg | $89.00 | — | 62 |
| Nox Amino | 10 mg | $75.00 | — | 55 |
| Peptiatlas | — | — | — | 51 |
| Taishijie | — | — | — | 51 |
| Taikangbio | — | — | — | 50 |
| MEI-PEPETIDE | 2 mg | $51.00 | — | 48 |
| DongCheng Peptide | — | — | — | 46 |
| Mandy | 5 mg | $81.00 | — | 43 |
| HongDa Peptide | — | $57.00 | — | 43 |
| zztai Peptide Ltd | — | — | — | 43 |
| MJT peptides | 2 mg | $57.00 | — | 39 |
| HK Peptide Ltd (hk peptides) | — | — | — | 37 |
| Cernum Biosciences | 5 mg | $69.99 | — | — |
| Cernum Biosciences | 10 mg | $94.99 | — | — |
| NG Peptide | 10 mg | $50.00 | — | — |
| Ruo Bio | 5 mg | $48.00 | — | — |
| Alpha Omega | 10 mg | $75.00 | — | — |
| Amino Sequence | 10 mg | $65.00 | — | — |
| Arcane Peptides | 5 mg | $50.00 | — | — |
| Atomik Labz | 20 mg | $110.00 | — | — |
| Atomik Labz | 12 mg | $85.00 | — | — |
| Atomik Labz | 10 mg | $55.00 | — | — |
| Biotech Peptides | 8 mg | $90.00 | — | — |
| Biotech Peptides | 12 mg | $109.00 | — | — |
| Biotech Peptides | — | $38.00 | — | — |
| Core Peptides | 12 mg | $117.00 | — | — |
| Core Peptides | 8 mg | $90.00 | — | — |
| Core Peptides | 10 mg | $43.00 | — | — |
| Core Peptides | 5 mg | $43.00 | — | — |
| Felix Chemical Supply | 5 mg | $42.99 | — | — |
| Felix Chemical Supply | 10 mg | $54.99 | — | — |
| Flawless Compounds | — | — | — | — |
| Genetic Peptide | 8 mg | $110.00 | — | — |
| Genetic Peptide | 12 mg | $125.00 | — | — |
| Genetic Peptide | 2 mg | $35.00 | — | — |
| Genetic Peptide | 5 mg | $35.00 | — | — |
| Genetic Peptide | 10 mg | $35.00 | — | — |
| Genetic Peptide | 15 mg | $35.00 | — | — |
| Genetic Peptide | 20 mg | $35.00 | — | — |
| Kimera Chems | — | $41.99 | — | — |
| Lumi Peptides | — | $105.00 | — | — |
| Lumi Peptides | — | $60.00 | — | — |
| Modern Research Peptides | 5 mg | $31.99 | — | — |
| Modern Research Peptides | 10 mg | $59.99 | — | — |
| Nextech Labs | 10 mg | $75.00 | — | — |
| Nova Peptides | 5 mg | $49.99 | — | — |
| Nova Peptides | 10 mg | $49.99 | — | — |
| Nova Peptides | 20 mg | $49.99 | — | — |
| Oneday Compounds | 10 mg | $74.99 | — | — |
| Paramount Peptides | 10 mg | $76.00 | — | — |
| Peptide Crafters | 11 mg | $85.00 | — | — |
| Peptide Crafters | 10 mg | $65.00 | — | — |
| Peptira | — | $89.00 | — | — |
| Pepvida Labs | 10 mg | $50.00 | — | — |
| Polaris Peptides | 10 mg | $65.00 | — | — |
| S1 Research | 10 mg | $44.00 | — | — |
| Solution Peptides | 20 mg | $110.00 | — | — |
| Solution Peptides | 12 mg | $85.00 | — | — |
| Solution Peptides | 10 mg | $55.00 | — | — |
| Soma Peptides | 6 mg | $89.00 | — | — |
| Soma Peptides | 12 mg | $89.00 | — | — |
| Soma Peptides | 10 mg | $80.00 | — | — |
| Southern Aminos | 10 mg | $53.40 | — | — |
| True Peptide | 10 mg | $70.00 | — | — |
| Welli Labs | — | $49.99 | — | — |
| Wellness Peptides | 5 mg | $75.00 | — | — |
| Wellness Peptides | 5 mg | $50.00 | — | — |
| Wellness Peptides | 10 mg | $50.00 | — | — |
Research
Background The Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH) study is a randomised controlled trial with the overall goal of examining the combined effect of exercise and the growth hormone-releasing hormone analogue tesamorelin on physical function.
source →Background Excess visceral abdominal fat (EVAF) is a prevalent metabolic complication among people living with HIV-1 (PLWH), occurring even in individuals with normal or mildly elevated body mass index (BMI).
source →The introduction of combination antiretroviral therapy (cART) has significantly reduced AIDS-related morbidity and mortality. However, the prevalence of age-associated comorbidities, particularly cardiovascular diseases (CVD), has increased, becoming a leading cause of mortality in people living with HIV.
source →Background HIV-associated lipodystrophy leads to visceral fat accumulation, metabolic complications, body image concerns, medication non-adherence, and increased cardiovascular risks.
source →Performance-enhancing drugs (PEDs) marketed as "research compounds" include unregulated peptides intended to modulate the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis.
source →Cognitive decline with age and other clinical conditions are linked with reduced hypothalamic-pituitary-adrenal (HPA) axis function.
source →Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement.
source →Background Injectable peptides are increasingly promoted for musculoskeletal recovery, tissue repair, and performance enhancements; however, clinical adoption has outpaced high-quality evidence and regulatory consensus.
source →Background Therapeutic peptides are short-chain amino acids that regulate cellular functions and facilitate biochemical processes. In recent years, there has been significant growth in the global market for therapeutic peptides and thus its popularity among patients.
source →Background In people with HIV who are virally suppressed with antiretroviral therapy, abdominal obesity (AO) is linked to neurocognitive impairment (NCI), potentially due to visceral adiposity, inflammation, and reduced insulin-like growth factor 1 (IGF-1).
source →In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity. This study is a single arm prospective study of tesamorelin therapy of patients with HIV lipodystrophy.
source →Background: People who have had a traumatic brain injury (TBI) often have trouble sleeping. TBI may also alter hormones, which can cause poor sleep. Researchers believe that a form of growth hormone releasing hormone (GHRH) might improve sleep in service members and veterans who have had a TBI.
source →Obesity is strongly associated with risk of cardiovascular disease (CVD). Data increasingly suggest that visceral adipose tissue (VAT) accumulation -- or increased abdominal fat -- is particularly deleterious to cardiovascular health, but further study is needed to test this idea.
source →The purpose of this observational, 10-year, prospective cohort study is to assess the potential safety concerns of long-term exposure to EGRIFTA® in HIV-infected subjects with abdominal lipohypertrophy compared with a similar group of subjects not exposed to EGRIFTA®.
source →RCT: tesamorelin-driven visceral-fat reduction was associated with an improved metabolic profile in HIV-infected patients.
source →Review of tesamorelin in the management of HIV-associated lipodystrophy — its FDA-approved indication.
source →Pivotal RCT: tesamorelin, a GHRH analogue, reduced visceral adipose tissue in HIV-infected patients with abdominal fat accumulation.
source →The purpose of this study is to examine the short-term effects of two different doses of growth hormone, compared to treatment with growth hormone releasing hormone, on the brain's secretion of growth hormone and the body's glucose metabolism.
source →The primary objective of the study is to determine the PK (tesamorelin) and PD (IGF-1) profiles of tesamorelin after a single 2 mg subcutaneous administration and after repeated administration once daily for 14 consecutive days.
source →Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation
source →The purpose of this study was to determine whether TH9507, a stabilized analogue of growth hormone-releasing factor (GRF), would have an effect on insulin sensitivity or control of diabetes in patients with type 2 diabetes.
source →